Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.00
Bid: 4.75
Ask: 5.25
Change: -0.375 (-6.98%)
Spread: 0.50 (10.526%)
Open: 5.375
High: 5.375
Low: 5.00
Prev. Close: 5.375
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

5 Feb 2020 17:38

RNS Number : 1217C
Genedrive PLC
05 February 2020
 

 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Lisa Miele, a Person Closely Associated with Gino Miele R&D Director and a PDMR, acquired 8,636 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at a price of 8.875p per today.

 

Following these purchases, Gino Miele's total beneficial interest is 66,979 Ordinary Shares, 0.2% of the issued share capital of the Company.

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Lisa Miele

 

 

2.

Reason for the notification

a.

Position/status

PCA of Gino Miele R&D Director

a.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

genedrive plc

b.

LEI

213800ZYODIRZ87Y4K14

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5 pence each

 

 

 

GB00B1VKB244

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)

 

Price(s)

Volume(s)

8.875p

8,636

 

d.

Aggregated information

·; Aggregated volume

·; Price

 

 

N/A

 

e.

Date of the transaction

2020-02-05

f.

Place of the transaction

London Stock Exchange, AIM

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

Stanford Capital Partners Limited (Joint Broker)

+44 (0)20 3815 8880

Patrick Claridge / John Howes

Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAXASEDDEEFA
Date   Source Headline
10th Apr 20187:00 amRNSPublication of Genedrive Performance Data in Gut
9th Apr 20189:06 amRNSDirectorate Change
4th Apr 20188:48 amRNSDirector/PDMR Shareholding
3rd Apr 20187:00 amRNSGenedrive® Hepatitis C test in Asia Pacific
27th Mar 20187:00 amRNSgenedrive signs distribution agreement for India
20th Mar 20183:40 pmRNSHolding(s) in Company
20th Mar 20187:00 amRNSInterim Results
13th Mar 20187:00 amRNSCommercial sales of Genedrive® HCV ID Kit begin
27th Feb 20187:00 amRNSgenedrive Receives Funding for TB Test Development
14th Feb 20187:00 amRNSNotice of Results
18th Jan 201811:59 amRNSHardman Res: Hep-C point-of-care test launched
17th Jan 20182:01 pmRNSHolding(s) in Company
17th Jan 20187:00 amRNSTrading update
16th Jan 20187:00 amRNSFirst Successful Field Evaluation of HCV Assay
13th Dec 20177:15 amRNSHardman Research: Remodelled for growth
7th Dec 20174:28 pmRNSDirector/PDMR Shareholding
29th Nov 20172:19 pmRNSResult of AGM
21st Nov 20177:00 amRNSgenedrive plc awarded Innovate UK grant
17th Nov 201711:25 amRNS2017 Annual Report and AGM Notice
14th Nov 20177:00 amRNSDistribution agreement with Sysmex Asia Pacific
8th Nov 20171:31 pmRNSDirectorate Change
6th Nov 20178:51 amRNSHolding(s) in Company
2nd Nov 20177:00 amRNSDistribution update for India
23rd Oct 20177:00 amRNSLaunches Genedrive® Hepatitis C test in Africa
18th Oct 20177:00 amRNSHolding(s) in Company
17th Oct 20177:00 amRNSPreliminary Results
16th Oct 20177:00 amRNSDistribution Agreement
11th Oct 20177:00 amRNSNotice of Preliminary Results
22nd Sep 20179:42 amRNSHolding(s) in Company
11th Sep 20177:00 amRNSGenedrive HCV Kit received CE Marking
27th Jul 20177:00 amRNS$1.4m Funding from US Department of Defense
13th Jul 20177:00 amRNSTrading Update
11th Apr 20177:00 amRNSHep C data presentation at EASL
5th Apr 201712:39 pmRNSDirector/PDMR Shareholding - Replacement
5th Apr 201711:17 amRNSDirector/PDMR Shareholding
30th Mar 20177:00 amRNSInterim Results
27th Mar 20177:00 amRNSHCV Assay submitted for CE IVD Certification
24th Mar 20177:00 amRNSNotice of Interim Results
8th Mar 20177:00 amRNSSuccessful Clinical Results - Genedrive HCV Assay
20th Feb 20177:00 amRNSDirector/PDMR Shareholding
6th Feb 20175:53 pmRNSHoldings in Company
27th Jan 20177:00 amRNSTrading Update
16th Jan 20177:00 amRNSUpdate on US Department of Defense Programme
23rd Dec 201610:48 amRNSDirector/PDMR Shareholding
30th Nov 20162:16 pmRNSResult of AGM
29th Nov 20167:00 amRNSUpdate on CFO Appointment
17th Nov 20167:00 amRNSCE-IVD Certification for Human Genotyping Test
11th Nov 20165:47 pmRNSNotice of AGM
11th Oct 20167:00 amRNSPreliminary Results for the year end 30 June 2016
21st Sep 20167:00 amRNSNotice of Preliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.